Article
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.
Lancet (London, England) - 1 Aug 1998
Snijders R J, Noble P, Sebire N, Souka A, Nicolaides K H
Abstract excerpt
BACKGROUND: Prenatal diagnosis of trisomy 21 currently relies on assessment of risk followed by invasive testing in the 5% of pregnancies at the highest estimated risk. Selection of the high-risk group by a combination of maternal age and second-trimester maternal serum biochemistry gives a detection rate of about 60%. We investigated assessment of risk by a combination of maternal age and fetal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.